| Archived Releases |
 |
Committee for Orphan Medicinal Products Recommends Orphan Designation for Biodel's Stabilized Glucagon for the Treatment of Congenital Hyperinsulinism
Jan 20, 2012
|
13.4 KB |
|
| |
DANBURY, Conn., Jan. 20, 2012 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) today reported that the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) has recommended that Biodel's Stabilized Glucagon for the treatment of congenital hyperinsulinism (CHI) be granted Orphan Medicinal Product Designation. The COMP's recom...
|
|
Biodel Inc. to Present at 30th Annual JPMorgan Healthcare Conference on January 12th, 2012
Jan 6, 2012
|
8.5 KB |
|
| |
DANBURY, Conn., Jan. 6, 2012 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) today announced that Dr. Errol De Souza, President and CEO of Biodel, will present a corporate update at the 30th Annual JPMorgan Healthcare Conference on Thursday, January 12, 2012 at 1:00 p.m. Pacific Time (4:00 p.m. Eastern Time).
The JPMorgan Healthcare Conference w...
|
|
Biodel Reports Fourth Quarter Fiscal Year 2011 Financial Results
Dec 6, 2011
|
21.0 KB |
|
| |
DANBURY, Conn., Dec. 6, 2011 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) today reported financial results for the fourth quarter ended September 30, 2011.
Fourth Quarter Operating Highlights
During Biodel's fourth quarter of fiscal year 2011, the company:
Selected a new lead candidate formulation of ultra-rapid-acting recombinant human in...
|
|
Biodel to Report Fourth Quarter Fiscal Year 2011 Financial Results on December 6, 2011
Dec 1, 2011
|
8.9 KB |
|
| |
DANBURY, Conn., Dec. 1, 2011 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) will issue its fourth quarter fiscal year 2011 financial results on December 6, 2011. Following the release of the company's financial results, Biodel's senior management will host a conference call to discuss the results and provide an update on the company's progress.
...
|
|
Biodel Reports Top-Line Results From Pump Study of Experimental Insulins
Sep 27, 2011
|
10.4 KB |
|
| |
DANBURY, Conn., Sept. 27, 2011 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) today announced top-line results from a Phase 1 clinical trial of BIOD-105 and BIOD-107 at Oregon Health and Sciences University to evaluate the pharmacokinetic, pharmacodynamic and infusion site tolerability profiles of these ultra-rapid-acting formulations of recombinant hu...
|
|
Biodel to Present at the JMP Securities Healthcare Conference on September 27th
Sep 22, 2011
|
8.4 KB |
|
| |
DANBURY, Conn., Sept. 22, 2011 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) today announced that Dr. Errol De Souza, President and Chief Executive Officer, will be presenting at the 6th Annual JMP Securities Healthcare Conference at the St. Regis Hotel in New York. The presentation is scheduled for Tuesday, September 27, 2011 at 8:30 a.m. ET (5:30 a...
|
|
Biodel to Present at the Wedbush 2011 Global Healthcare Conference on August 16
Aug 15, 2011
|
8.3 KB |
|
| |
DANBURY, Conn., Aug. 15, 2011 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) today announced that management will be presenting at the Wedbush 2011 Life Sciences Conference in New York. The presentation is scheduled for Tuesday, August 16 at 2:25 p.m. EDT (11:25 a.m. PDT). To listen to the live webcast or a replay of the presentation, please visit th...
|
|
Biodel Reports Third Quarter Fiscal Year 2011 Financial Results
Aug 4, 2011
|
21.3 KB |
|
| |
DANBURY, Conn., Aug. 4, 2011 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) today reported financial results for the third quarter ended June 30, 2011.
Third Quarter Operating Highlights
During Biodel's third quarter of fiscal year 2011, the company:
completed Phase 1 testing of two new ultra-rapid-acting formulations of recombinant human in...
|
|
Biodel to Report Third Quarter Fiscal Year 2011 Financial Results on August 4, 2011
Aug 1, 2011
|
8.6 KB |
|
| |
DANBURY, Conn., Aug. 1, 2011 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) will issue its third quarter fiscal year 2011 financial results on August 4, 2011. Following the release of the company's financial results, Biodel's senior management will host a conference call to discuss the results and provide an update on the company's progress.
August...
|
|
Biodel to Raise $30 Million Through Registered Direct Offering
May 13, 2011
|
10.6 KB |
|
| |
DANBURY, Conn., May 13, 2011 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) today announced that it has entered into definitive agreements with a group of institutional investors, including Great Point Partners, LLC and Orbimed Advisors, LLC, to sell approximately 12.2 million shares of its common stock, 1.7 million shares of its Series A Convertible P...
|
|
Independent Investigator Initiates Phase 1 Study of Biodel's Ultra-Rapid-Acting Insulin Formulations in Patients Using Insulin Pumps
May 10, 2011
|
12.2 KB |
|
| |
DANBURY, Conn., May 10, 2011 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) announced today that an independent investigator initiated a pump trial of Biodel's two ultra-rapid-acting formulations of recombinant human insulin.
The formulations, BIOD-105 and BIOD-107, are designed to result in more rapid insulin action compared to currently marketed ...
|
|
Biodel Reports Second Quarter Fiscal Year 2011 Financial Results
May 5, 2011
|
21.4 KB |
|
| |
DANBURY, Conn., May 5, 2011 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) today reported financial results for the quarter ended March 31, 2011.
Second Quarter Fiscal Year 2011 Financial Results
Biodel reported a net loss for the three months ended March 31, 2011 of $5.4 million, or $0.21 per share, compared to a net loss of $10.4 million, or $...
|
|
Biodel to Report Second Quarter Fiscal Year 2011 Financial Results on May 5, 2011
May 3, 2011
|
8.6 KB |
|
| |
DANBURY, Conn., May 3, 2011 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) will issue its second quarter fiscal year 2011 financial results on May 5, 2011. Following the release of the company's financial results, Biodel's senior management will host a conference call to discuss the results and provide an update on the company's progress.
May 5, 20...
|
|
Biodel Announces Appointment of Dr. Brian J.G. Pereira as Board Chairman; Dr. Charles A. Sanders to Remain on Board
Mar 30, 2011
|
10.1 KB |
|
| |
DANBURY, Conn., March 30, 2011 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) announced today the appointment of Dr. Brian J.G. Pereira as board chairman effective immediately. Dr. Pereira has served on the board since November 2007. Dr. Charles A. Sanders, who served as chairman since March 2010 after joining the board in August 2006, will continue ...
|
|
Biodel Announces Accelerated Development Plan for Ultra-Rapid-Acting Insulins: Initiate Phase 2 in 2011; Phase 3 Pivotal Trials in 2012
Mar 14, 2011
|
13.6 KB |
|
| |
DANBURY, Conn., Mar. 14, 2011 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) announced today that it has selected two new formulations of recombinant human insulin for clinical testing and is accelerating clinical development plans of these mealtime insulin drug candidates. The new formulations, BIOD-105 and BIOD-107, are designed to result in more ra...
|
|
Biodel Inc. to Present at the Roth 23rd Annual OC Growth Stock Conference on March 16, 2011
Mar 8, 2011
|
8.7 KB |
|
| |
DANBURY, Conn., March 8, 2011 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) announced today that Dr. Errol De Souza, President and CEO of Biodel, will present a corporate update at the Roth 23rd Annual OC Growth Stock Conference on March 16, 2011 at 1:00 p.m. Pacific Time (4:00 p.m. Eastern Time). The update will include information about the developm...
|
|
Biodel Reports First Quarter Fiscal Year 2011 Financial Results
Feb 3, 2011
|
20.6 KB |
|
| |
DANBURY, Conn., Feb. 3, 2011 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) today reported financial results for the quarter ended December 31, 2010.
First Quarter Fiscal Year 2011 Financial Results
Biodel reported a net loss for the three months ended December 31, 2010 of $5.3 million, or $0.20 per share, compared to a net loss of $11.1 million...
|
|
Biodel to Report First Quarter Fiscal Year 2011 Financial Results on February 3, 2011
Jan 31, 2011
|
8.6 KB |
|
| |
DANBURY, Conn., Jan. 31, 2011 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) will issue its first quarter fiscal year 2011 financial results on February 3, 2011. Following the release of the company's financial results, Biodel's senior management will host a conference call to discuss the results and provide an update on the company's progress.
Feb...
|
|
Biodel Inc. to Present at 29th Annual JPMorgan Healthcare Conference on January 13th, 2011
Jan 6, 2011
|
8.7 KB |
|
| |
DANBURY, Conn., Jan. 6, 2011 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) today announced that Dr. Errol De Souza, President and CEO of Biodel, will present a corporate update at the 29th Annual JPMorgan Healthcare Conference on Thursday, January 13, 2011 at 9:30 a.m. Pacific Time (12:30 p.m. Eastern Time). The update will include information about t...
|
|
|
